MX376241B - Uso de anticuerpos anti-il-1a en el tratamiento de enfermedades vasculares y sus complicaciones. - Google Patents

Uso de anticuerpos anti-il-1a en el tratamiento de enfermedades vasculares y sus complicaciones.

Info

Publication number
MX376241B
MX376241B MX2015004286A MX2015004286A MX376241B MX 376241 B MX376241 B MX 376241B MX 2015004286 A MX2015004286 A MX 2015004286A MX 2015004286 A MX2015004286 A MX 2015004286A MX 376241 B MX376241 B MX 376241B
Authority
MX
Mexico
Prior art keywords
complications
vascular disease
treating vascular
chance
expected
Prior art date
Application number
MX2015004286A
Other languages
English (en)
Spanish (es)
Other versions
MX2015004286A (es
Inventor
John Simard
Original Assignee
Xbiotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xbiotech Inc filed Critical Xbiotech Inc
Publication of MX2015004286A publication Critical patent/MX2015004286A/es
Publication of MX376241B publication Critical patent/MX376241B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • C07K16/245IL-1
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
MX2015004286A 2012-10-04 2013-10-01 Uso de anticuerpos anti-il-1a en el tratamiento de enfermedades vasculares y sus complicaciones. MX376241B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261709754P 2012-10-04 2012-10-04
PCT/US2013/062903 WO2014055544A1 (en) 2012-10-04 2013-10-01 Treating vascular disease and complications thereof

Publications (2)

Publication Number Publication Date
MX2015004286A MX2015004286A (es) 2015-08-06
MX376241B true MX376241B (es) 2025-03-06

Family

ID=50432830

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015004286A MX376241B (es) 2012-10-04 2013-10-01 Uso de anticuerpos anti-il-1a en el tratamiento de enfermedades vasculares y sus complicaciones.

Country Status (12)

Country Link
US (3) US20140099321A1 (enExample)
EP (3) EP4628162A3 (enExample)
JP (1) JP6460993B2 (enExample)
KR (2) KR102296017B1 (enExample)
CN (2) CN113018431A (enExample)
AU (1) AU2013327501B2 (enExample)
CA (1) CA2886747C (enExample)
HK (1) HK1211960A1 (enExample)
IL (1) IL237765B (enExample)
MX (1) MX376241B (enExample)
RU (1) RU2671955C2 (enExample)
WO (1) WO2014055544A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110311547A1 (en) 2010-06-18 2011-12-22 Xbiotech, Inc. Arthritis Treatment
KR20210128021A (ko) 2010-08-23 2021-10-25 얀센 바이오테크 인코포레이티드 종양성 질병들에 대한 치료
US9724409B2 (en) 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease
ES2695102T3 (es) 2011-09-23 2019-01-02 Xbiotech Inc Tratamiento para la caquexia
US9545441B2 (en) 2012-09-18 2017-01-17 Xbiotech, Inc. Treatment of diabetes
MX2019009798A (es) 2017-02-16 2020-01-30 Xbiotech Inc Tratamiento de la hidradenitis supurativa.
JP2022531328A (ja) * 2019-05-03 2022-07-06 ユニバーシティ・オブ・チューリッヒ 脳虚血再灌流傷害の治療
KR102652849B1 (ko) 2022-03-14 2024-04-01 한국화학연구원 극성 아라미드 나노섬유로 제조한 하이드로겔

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH652145A5 (de) 1982-01-22 1985-10-31 Sandoz Ag Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
RU2235541C2 (ru) * 1994-10-04 2004-09-10 Эмори Юниверсити Лечение атеросклероза и других сердечно-сосудистых и воспалительных заболеваний
JP2003500069A (ja) * 1999-05-24 2003-01-07 インタールーキン ジェネティックス インク 再狭窄の診断及び治療薬
CA2458622A1 (en) * 2001-08-24 2003-03-06 Maine Medical Center Research Institute Copper-dependent non-traditional pro-inflammatory cytokine export and methods, compositions and kits relating thereto
WO2004100987A2 (en) * 2003-05-06 2004-11-25 Regeneron Pharmaceuticals, Inc. Methods of using il-1 antagonists to treat neointimal hyperplasia
PL3085773T3 (pl) * 2008-05-30 2021-01-11 Xbiotech, Inc Zastosowanie przeciwciał il-1 alfa
SG176265A1 (en) * 2009-05-29 2012-01-30 Xoma Technology Ltd CARDIOVASCULAR RELATED USES OF IL-1ß ANTIBODIES AND BINDING FRAGMENTS THEREOF
JP5812669B2 (ja) 2011-04-27 2015-11-17 キヤノン株式会社 画像処理装置および画像処理方法およびコンピュータプログラム。

Also Published As

Publication number Publication date
CN104684929A (zh) 2015-06-03
IL237765A0 (en) 2015-05-31
US20140099321A1 (en) 2014-04-10
RU2671955C2 (ru) 2018-11-08
KR102429919B1 (ko) 2022-08-05
EP4628162A2 (en) 2025-10-08
US20210403548A1 (en) 2021-12-30
CN113018431A (zh) 2021-06-25
IL237765B (en) 2019-06-30
AU2013327501A1 (en) 2015-04-02
CA2886747A1 (en) 2014-04-10
EP4628162A3 (en) 2025-12-03
AU2013327501B2 (en) 2018-08-09
MX2015004286A (es) 2015-08-06
WO2014055544A1 (en) 2014-04-10
US20180057585A1 (en) 2018-03-01
JP6460993B2 (ja) 2019-01-30
EP2904010A1 (en) 2015-08-12
KR20210108496A (ko) 2021-09-02
JP2015531397A (ja) 2015-11-02
EP2904010A4 (en) 2016-06-01
HK1211960A1 (en) 2016-06-03
KR20150063076A (ko) 2015-06-08
CA2886747C (en) 2023-12-05
RU2015110635A (ru) 2016-11-27
EP3524621A1 (en) 2019-08-14
KR102296017B1 (ko) 2021-09-01

Similar Documents

Publication Publication Date Title
MX376241B (es) Uso de anticuerpos anti-il-1a en el tratamiento de enfermedades vasculares y sus complicaciones.
EP4349343A3 (en) Expression of mirnas in placental tissue
NZ595331A (en) Ex-vivo treatment of immunological disorders with pkc-theta inhibitors
NZ602219A (en) Methods and compositions for treating degos’ disease
JOP20140344B1 (ar) تركيبات وطرق لتقليل المضاعفات السلبية العظمي للقلب والاوعية الدموية
MX2011007397A (es) Inhibidores de dpp-iv para el tratamiento de la diabetes en pacientes pediatricos.
ZA201700196B (en) Methods for treating high cardiovascular risk patients with hypercholesterolemia
AR097178A1 (es) Diagnóstico y terapias anticáncer que comprenden células madre cancerosas
LT2013018A (lt) Farmacinė kompozicija, skirta gydyti diabetą ir metabolinius sutrikimus
MX2010006650A (es) Materiales y metodos para el tratamiento de proliferacion vascular ocular patologica.
WO2015067755A3 (en) Novel methods and antibodies for treating coagulapathy
EP2670435A1 (en) Use of anti-dkk1 monoclonal antibody for treatment of liver cancer
JP2015531397A5 (enExample)
UY33533A (es) siRNA DIRIGIDO AL VEGFA Y A MÉTODOS DE TRATAMIENTO IN VIVO
EP4279128A3 (en) Novel antibody binding to tfpi and composition comprising the same
MX2014005209A (es) Un medicamento para tratar la enfermedad del ojo anterior que comprende rebamipida y un agente de retencion de lagrimas.
GEP201706716B (en) Optimised subcutaneous therapeutic agents
MX2014010940A (es) El uso de antitrombina en el tratamiento de preeclampsia.
MX354981B (es) Medicamento para tratamiento terapeutico y/o mejoramiento de sepsis.
WO2012106497A3 (en) Selection and treatment of subjects
WO2013078376A3 (en) Isoxazole treatments for diabetes
HK1213921A1 (zh) 用於減少在植入支架後的糖尿病患者的主要不良心血管事件(mace)的雙重可變結構域(dvd)免疫球蛋白
Liu et al. Preventive effects of modified chitosan medical anti-adhesion membrane on postoperative intra-abdominal adhesion
张承磊 The treatment strategy of special distal landing zones in endovascular repair of abdominal aortic aneurysm
RU2010127731A (ru) Способ лечения гнойно-воспалительных осложнений у онкоурологических больных

Legal Events

Date Code Title Description
FG Grant or registration
PD Change of proprietorship

Owner name: JANSSEN BIOTECH, INC.